Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SK-BR-3 Neratinib
0.00031623
EGFR/HER2
RTK
 0.8693 0.01462
SK-BR-3 Neratinib
0.001
EGFR/HER2
RTK
 0.6239 0.03904
SK-BR-3 Neratinib
0.0031623
EGFR/HER2
RTK
 0.2677 0.11147
SK-BR-3 Neratinib
0.01
EGFR/HER2
RTK
 0.0886 0.16139
SK-BR-3 Neratinib
0.031623
EGFR/HER2
RTK
 0.0194 0.21796
SK-BR-3 Neratinib
0.1
EGFR/HER2
RTK
 -0.0389 0.24447
SK-BR-3 Neratinib
0.31623
EGFR/HER2
RTK
 -0.1447 0.30230
SK-BR-3 Neratinib
1.0
EGFR/HER2
RTK
 -0.2514 0.36911
SK-BR-3 Neratinib
3.1623
EGFR/HER2
RTK
 -0.2530 0.36589
SK-BR-3 Tivantinib
0.001
MET
RTK
 1.0421 0.00349
SK-BR-3 Tivantinib
0.0031623
MET
RTK
 1.0607 0.00171
SK-BR-3 Tivantinib
0.01
MET
RTK
 1.0436 0.00173
SK-BR-3 Tivantinib
0.031623
MET
RTK
 1.0714 0.00950
SK-BR-3 Tivantinib
0.1
MET
RTK
 0.8779 0.04583
SK-BR-3 Tivantinib
0.31623
MET
RTK
 0.4015 0.18097
SK-BR-3 Tivantinib
1.0
MET
RTK
 -0.3029 0.52635
SK-BR-3 Tivantinib
3.1623
MET
RTK
 -0.3294 0.54882
SK-BR-3 Tivantinib
10.0
MET
RTK
 -0.3523 0.53518
SK-BR-3 Cediranib
0.001
VEGFR/cKIT
RTK
 0.9992 0.00168
SK-BR-3 Cediranib
0.0031623
VEGFR/cKIT
RTK
 1.0411 -0.00585
SK-BR-3 Cediranib
0.01
VEGFR/cKIT
RTK
 1.0779 0.00389
SK-BR-3 Cediranib
0.031623
VEGFR/cKIT
RTK
 1.1220 -0.00617
SK-BR-3 Cediranib
0.1
VEGFR/cKIT
RTK
 1.0427 0.00161
SK-BR-3 Cediranib
0.31623
VEGFR/cKIT
RTK
 1.0293 -0.01040
SK-BR-3 Cediranib
1.0
VEGFR/cKIT
RTK
 0.9788 0.00295